Lung Therapeutics, Inc., an Austin, TX-based clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, closed a $36m Series C financing round.
Bios Partners participated in the Series C round.
Led by Brian Windsor, PhD, CEO, Lung Therapeutics leverages research in orphan, pulmonary indications for which there are unmet medical needs.
The company intends to use the funds to complete:
– the first and only Phase II clinical trial in patients with Loculated Pleural Effusions, a serious complication of pneumonia; as well as
– a healthy volunteer Phase I clinical trial for its second product candidate, LTI-03, which is in development for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Lung Therapeutics has raised a total of $53m in funding to date.